

1 **A New Algorithm for Incidental Pancreatic Cyst Detection**

2

3 M. Álvaro Berbís¹, Juan Moreno-Vedia², Félix Paulano-Godino¹, Ainhoa Viteri¹, Meritxell
4 Riera-Marín², Daniel Cañadas-Gómez², Romina Trotta¹, Beatriz Forastero¹, Luis Luna¹,
5 Javier García López², Antonio Luna³, Júlia Rodríguez-Comas²

6

7 ¹ Department of Radiology, HT Médica, San Juan de Dios Hospital, 14012 Córdoba, Spain.

8 ² Scientific and Technical department, Sycai Technologies S.L., 08018 Barcelona, Spain.

9 ³ Department of Radiology, HT Médica, Clínica las Nieves, 23007, Jaén, Spain

10

11

12 **Corresponding author:**

13 M. Álvaro Berbís, PhD

14 Radiology Department, HT Médica, Hospital San Juan de Dios de Córdoba

15 Avda. Brillante 106, 14012 Córdoba, Spain

16 a.berbis@htime.org

17

18

19 **ABSTRACT**

20 **Objectives:** To develop an accurate, state-of-the-art algorithm for the incidental detection of
21 pancreatic cystic lesions (PCLs) on computerized tomography (CT) and magnetic resonance
22 imaging (MRI) scans.

23 **Methods:** A SwinT-Unet-based architecture was developed for the incidental detection of
24 PCLs. The algorithm was trained and validated on a robust dataset of retrospective CT and
25 MRI studies collected from HT Médica centers located in eight different cities using scanners
26 fabricated by four different manufacturers.

27 **Results:** Our algorithm was able to detect 91.6% of the confirmed PCLs in the initial dataset
28 with 91.6% sensitivity and 92.3% specificity, while 91.7% of the healthy controls were also
29 correctly identified. Furthermore, our tool was remarkably capable of classifying these PCLs
30 as mucinous or non-mucinous, determining their location within the pancreas with an
31 accuracy of 88.5%, and identifying the presence of calcifications or scars within the PCLs
32 with an accuracy of 96%.

33 **Conclusions:** By integrating radiological data and state-of-the-art artificial intelligence
34 techniques, we have developed an efficient tool for the incidental identification and initial
35 characterization of PCLs, which present a substantial prevalence within the global
36 population. Our algorithm facilitates early diagnosis of pancreatic abnormalities, which could
37 have a profound impact on patient management and prognosis, particularly in the case of
38 PCLs with malignant potential.

39

40 **Keywords:** Pancreatic Cysts, Computerized Tomography, Magnetic Resonance Imaging,
41 Incidental Findings, Artificial Intelligence, SwinT-Unet.

42

43 INTRODUCTION

44 Pancreatic cancer (PC) currently ranks as the twelfth most common type of cancer globally
45 [1], and it is further expected to become the second leading cause of cancer-related mortality
46 by 2030 [2]. Moreover, PC is one of the most lethal types of cancer, with a 5-year survival
47 rate inferior to 10% [3]. The delayed onset of PC symptoms, often appearing when metastasis
48 has already occurred, results in up to 85% of patients no longer being eligible for surgical
49 resection, which has a profound negative impact on their prognosis [4,5].

50 Many research efforts are currently focused on the identification of biomarkers for early PC
51 detection, aiming to improve patient outcomes. However, only one of these biomarkers, the
52 serum carbohydrate antigen 19-9, has been approved by the US Food and Drug
53 Administration (FDA), and only as a therapy response and disease relapse monitoring
54 marker, as its predictive value is too low for population screening purposes [6]. Nonetheless,
55 there is an opportunity for early PC diagnosis in patients presenting pancreatic cystic lesions
56 (PCLs), as some of them are well-known precursors for this malignancy. The widespread
57 adoption of advanced imaging techniques, particularly computed tomography (CT) and
58 magnetic resonance imaging (MRI), has led to an increased identification of conditions
59 unrelated to the initially suspected diagnosis. These incidental findings can indeed be
60 fortunate discoveries when they entail the early detection of a potentially treatable
61 malignancy. Unsuspected PCLs have a prevalence of 2.6% in CT scans [7] and of 13.5–
62 19.6% in MRI studies [8,9], and both show a strong correlation with advanced age.
63 Unexpectedly, a recent study found a much higher prevalence (49.1%) of incidental PCLs in
64 healthy individuals, which also increased with body mass index and age [10].

65 PCLs can have a non-neoplastic (pseudocysts) or a neoplastic nature. Among the latter,
66 serous cystadenomas (SCA) are typically regarded as benign [11], while mucinous cysts are
67 often associated with malignant potential. Intraductal papillary mucinous neoplasms (IPMN)
68 and mucinous cystic neoplasms (MCN) are two well-known PC precursors. IPMNs can arise
69 from the side branches, the main pancreatic duct, or a combination of both, with a notably
70 higher prevalence of PC found in main duct IPMNs [12]. Thus, this distinction has a direct
71 impact on patient management and prognosis. PC cases arising from PCLs have been
72 proposed to follow a systematic model in which malignancy progression occurs over several
73 years, thus offering an opportunity for early diagnosis [13,14]. However, differentiation
74 between the different types of PCLs is challenging, and although the presence of some
75 specific features can be indicative of malignancy [15,16], these signs are sometimes not
76 enough to confidently distinguish between benign and malignant PC precursors.
77 Nevertheless, early detection of PCLs is essential to improve patient outcomes and reduce
78 the economic strain on healthcare systems, as it would allow more informed, enhanced
79 decision-making regarding lesion management and monitoring, thus potentially preventing
80 progression to PC.

81 Artificial intelligence (AI) tools are poised to play a crucial role in the early detection of
82 PCLs in CT and MR images. These algorithms have the potential to accurately identify and
83 define lesion boundaries and to extract essential qualitative and quantitative information from
84 their features, thus improving diagnostic precision. The implementation of these tools would
85 also help to streamline the workflow in radiology departments, providing valuable assistance
86 to radiologists in the diagnostic process and reducing their workload. The capability of
87 convolutional neural networks (CNNs) to learn the spatial hierarchies of features from input

88 data in an automatic and adaptive manner makes them exceptionally useful for extracting
89 information from medical images. This capability allows CNNs to learn complex patterns at
90 different levels of abstraction, recognize patterns independently of their spatial location, and
91 even identify new patterns not obvious to the human eye. Moreover, depending on the
92 specific dataset they are trained on, CNNs can work with multiple types of imaging studies
93 (ultrasound, CT, MRI, etc.) and perform a wide variety of tasks (detection, segmentation,
94 classification, etc.). Applied to medical images, the AI model presented in this manuscript,
95 based on the SwinT-Unet architecture, offers exceptional segmentation accuracy and
96 remarkable generalization ability, allowing the discrimination of structures at the pixel level.
97 The results showed an outstanding performance of our algorithm, achieving 91.6%
98 sensitivity and 92.3% specificity in the incidental detection of PCLs, while also
99 demonstrating a remarkable capacity to further characterize the lesion by classifying it as
100 mucinous or non-mucinous, accurately determining its location within the pancreas, and
101 identifying the presence of calcifications or scars within the PCLs. Our findings confirm a
102 significant prevalence of PCLs within our study population, highlighting the crucial support
103 a tool like ours might provide through the early diagnosis of pancreatic abnormalities and the
104 significant impact this would have on patient management and prognosis, particularly in the
105 case of PLCs with malignant potential.

106

107 **MATERIALS AND METHODS**

108 *Patients*

109 The total cohort included 43.3% women (**table 1**). This initial cohort was divided into two
110 subgroups: the control group included 56.3% of the patients (37.9% women, **table 2**), while
111 the second group, comprising patients who had been diagnosed with a PCL, included 43.7%
112 of the study population (**table 3**). Both groups showed a similar age distribution, and women
113 and men were equally represented in the PCL group, which was further characterized to
114 analyze the performance of our algorithm.

115

116 *Imaging*

117 Image studies were acquired at different HT Médica medical centers located in the Spanish
118 cities of Jaén, Córdoba, El Ejido, Huelva, Cádiz, Jerez de la Frontera, Algeciras, and Sevilla,
119 from January 2018 to December 2021, using scanners developed by the following
120 manufacturers (**tables 1–3**): Canon Medical Systems (Otawara, Japan), GE Healthcare
121 (Chicago, IL, United States), Philips (Amsterdam, The Netherlands), and Siemens
122 Healthineers (Erlangen, Germany). Demographic data of the patients, including age and
123 gender, were collected from HT Médica’s radiological information system.

124

125 *Segmentation and feature extraction*

126 A team of radiologists, each of them with more than five years of experience, manually
127 delineated the pancreas and PCLs in all the images, slice by slice, using the 3D modeling tool
128 available in the Philips IntelliSpace Portal (v12.1). The segmentations were subsequently
129 exported in RTSTRUCT format. To ensure agreement between raters, collaborative

130 segmentation, and consensus resolution were employed, minimizing discrepancies in the
131 assessment process.

132

133 *Algorithm development*

134 The proposed model (**fig1**) is based on the SwinT-Unet [17] architecture, a further
135 development from the U-Net [18] that aims to predict objects on an image with pixel-wise
136 accuracy. Our model includes an encoder block, to reduce input resolution, and a U-Net
137 decoder with dual-scale information modules. The encoder is an attention-based model with
138 blocks that capture information at multiple scales, similar to that proposed by Atek et al. [17].
139 The input image is processed through multiple Swin transformer blocks performing attention
140 operations and feature transformation. These blocks are responsible for feature extraction at
141 various scales, allowing the model to capture both the fine details and high-level abstract
142 features. After information passes through the encoder, the architecture adopts a U-Net-like
143 structure [18] to perform segmentation. The decoder takes the features extracted by the
144 encoder and uses them to generate a segmentation mask of the same resolution as the original
145 input. Additionally, the decoder incorporates dual-scale information modules to merge
146 features from different resolution levels that allow the model to integrate detailed and
147 contextual information at different scales, thus improving segmentation accuracy, especially
148 in areas with fine details or small features. This ability to process features and key points at
149 different levels is crucial for the network to learn the features that best characterize big
150 organs, such as the liver, as well as small lesions with different shapes and textures, such as
151 PCLs. The network was specifically trained to learn the position and shape of the liver,
152 kidneys, and pancreas, as well as a wide range of benign, pre-malignant, and malignant

153 lesions present in the training set corresponding to the aforementioned organs. The model
154 proposed here further includes two more steps: (1) a pre-processing step, prior to the
155 inference of the neural network, that normalizes the input image by applying a Soft-Tissue
156 Normalization [19], and (2) a post-processing step after the inference the filters out potential
157 detections of the network that have no anatomical meaning, such as lesions belonging to an
158 organ which they are not in direct contact with or predictions present in parts of the study
159 where the abdomen is not visible yet.

160

161 *Statistical analysis*

162 The Kolmogorov–Smirnov test was used to assess normality. Categorical variables are
163 presented as total numbers and percentages, and continuous variables are presented as
164 medians and interquartile ranges (IQRs) for non-normally distributed data. The chi-square
165 (χ^2) test was used to analyze group differences for categorical variables, while the Mann–
166 Whitney U test was used for continuous variables. Results were considered statistically
167 significant if $p < 0.05$. Statistical analyses were conducted using the SPSS Statistics, version
168 29.0.0.0 (IBM, Armonk, NY, United States).

169

170 **RESULTS**

171 *Patient's characteristics*

172 The median age of the patients included in the present study was 66 years old. The 61–80
173 age range was the most represented, consistent with the expected increase in CT and MRI
174 scans performed as the population ages. Women accounted for 43.3% of the initially

175 evaluated patients (**table 1**). The recruited cohort was divided into two groups: one group
176 with confirmed PCLs, including 43.7% of the patients, and a control group of healthy
177 individuals. Both groups showed a similar age distribution, and women and men were equally
178 represented in the PCL group (**tables 2 and 3**).

179 Among these PCL lesions, 61.1% of them were identified as non-mucinous (serous cystic
180 neoplasms (SCN), pseudocysts) and 38.9% were classified as mucinous (MCNs, IPMNs).
181 Within the non-mucinous group, 93.8% of them were SCNs or pseudocysts; additionally,
182 3.8% of non-subclassified benign lesions and 2.5% of undetermined non-mucinous lesions
183 were detected (**table 4**). The prevalence of both mucinous and non-mucinous lesions
184 increased with age, with mucinous cases associated with a higher median age ($p<0.001$).
185 Notably, a higher percentage of patients with mucinous lesions fell within the 61–80 age
186 range, consistent with the expectation of a higher lesion incidence in older patients [10].

187

188 *Incidental finding of PCLs*

189 Out of the initial dataset, 43.7% of the cases were confirmed as true positives for a PCL,
190 based on radiological evidence. This prevalence is in alignment with the existing literature,
191 which reports the presence of PCLs in up to 49.1% of the adult population [10]. Our
192 algorithm successfully detected 91.6% of the lesions, while 8.4% were missed (false
193 negatives). Furthermore, among the control population, the algorithm accurately identified a
194 healthy pancreas in 91.7% of the cases but presented 7.7% of false positives.

195 Overall, our SwinT-Unet-based model showed 91.6% sensitivity and 92.3% specificity in the
196 detection of PCLs. These results confirm the high precision and reliability of our AI-based

197 approach in distinguishing between cystic lesions and non-cystic structures within the
198 pancreas, underscoring the potential of AI technology to enhance the accuracy and efficiency
199 of pancreatic lesion detection, thereby facilitating early diagnosis and treatment planning for
200 patients with pancreatic abnormalities.

201

202 *Characterization of PCLs: mucinous vs. non-mucinous classification and location*

203 While the majority of pancreatic cysts carry a low risk of malignancy, some are recognized
204 as premalignant lesions capable of progressing into mucin-producing adenocarcinoma.
205 Consequently, the identification of these cysts often triggers heightened anxiety in the patient
206 and prompts additional medical investigations to assess the potential for malignancy [20,21].

207 While the primary objective in this study was the incidental detection of PCLs, the
208 classification of these cysts as mucinous (IPMNs, MCNs) or non-mucinous (SCNs,
209 pseudocysts) [22] was also addressed, achieving an accuracy of 73.3% in the classification
210 of PLCs as mucinous (**fig2**).

211 Furthermore, we analyzed the spatial distribution of the PCLs within the pancreas, with the
212 algorithm demonstrating a high accuracy (88.5%) in categorizing the cysts as head, body, or
213 tail, according to their location. Specifically, the algorithm was capable of correctly
214 determining the location of the lesion at the head or the uncinate process of the pancreas with
215 an accuracy of 86%, at the body with an accuracy of 92.6%, and at the tail with an accuracy
216 of 75.7%.

217 Additionally, we conducted a thorough examination for the presence of calcifications or scars
218 within the cystic lesions, achieving an accuracy of 96% in their identification. This was

219 crucial to assess the presence of potential signs of malignancy or chronic inflammation within
220 the PCL. To achieve this, several image feature extraction algorithms were applied to study
221 the high increments of Hounsfield Units (HU) on small sliding windows passed through
222 patches of the image where the lesion was detected. A map of the increased direction of the
223 HU within the sliding window is thus generated and, by calculating its maximum, the
224 candidates to potential scars (understood as groups of pixels with a high HU, since they have
225 a great bone component that is aligned towards a defined direction within the PCL) are
226 extracted.

227 This comprehensive characterization of the PCL provides valuable insights into the diverse
228 nature of the lesion, supporting clinicians in diagnostic decision-making and risk
229 stratification for further management strategies.

230

231 **DISCUSSION**

232 Considerable efforts have been employed to try to distinguish between the different types of
233 PCLs, as this step is essential to correctly stratify the malignant potential of the lesion so the
234 best patient management can be provided. Duh et al. developed an AG-Net model capable of
235 identifying PCLs on CT scans with 93.1% sensitivity and 81.8% specificity, further
236 classifying them into two groups (IPMN and MCN vs pseudocysts and SCAs) [23]. Vilas-
237 Boas et al. designed a CNN for the automatic detection of mucinous PCLs. The algorithm,
238 trained on images retrieved from EUS examination videos, achieved 98.5% accuracy, 98.3%
239 sensitivity, and 98.9% specificity in the classification of PCLs as mucinous or non-mucinous
240 [24]. Yang et al. developed a random forest (RF) model capable of differentiating between

241 serous and mucinous pancreatic cystadenomas based on the analysis of radiomics texture
242 features extracted from CT scans. Their algorithm achieved 0.83 accuracy, 0.85 sensitivity,
243 and 0.83 specificity for a slice thickness of 5 mm [25]. Shen et al. compared the performance
244 of a support vector machine (SVM) model, an RF algorithm, and an artificial neural network
245 (ANN) in differentiating among SCAs, MCNs, and IPMNs using eight clinical factors and
246 nine radiomics features extracted from CT scans [26]. The RF classifier offered the best
247 results, achieving an accuracy of 79.59% and F1 scores of 0.7500 for the differentiation of
248 IPMNs, 0.8182 for MCNs, and 0.8077 for SCAs. Gao et al. designed a CNN to identify
249 pancreatic anomalies, including PCLs, on MRI images [27]. The authors employed 504
250 original pre-treatment MRI studies to train their model. As most of the patches within the
251 images corresponded to carcinoma, they augmented the number of images for the other
252 conditions with the help of a generative adversarial network (GAN), creating synthetic
253 images based on real ones up to a total of 35735 patches for the training dataset. The CNN
254 trained on this augmented dataset offered its best results when a synthetic to real images ratio
255 of 40:1 was used, achieving an AUC of 0.9147 for the identification of carcinomas, 0.8486
256 for benign ductal diseases, 0.9126 for benign cystic diseases, 0.7189 for inflammatory
257 diseases, 0.9301 for pancreatic neuroendocrine tumors, and 0.8880 for solid pseudopapillary
258 tumors.

259 The number of studies exploring the incidental finding of PCLs via AI approaches is much
260 reduced. Kooragayala et al. employed a publicly available natural language processing (NLP)
261 software to identify incidental findings on CT scan reports [28]. The authors created a list of
262 specific terms (including IPMN, pancreatic cyst, and pancreatic ductal dilation) to identify
263 pancreatic findings that were used as parameters to train the algorithm on a subset of 28

264 patients who had undergone pancreatic resection for known pancreatic lesions. This
265 algorithm achieved an accuracy of 0.987 on a validation set of 400 CT scan reports. Their
266 optimized model was subsequently applied to 18769 CT studies from patients admitted at
267 their institution for trauma and findings of interest were identified in 232 of them, including
268 potential IMPNs (48 patients), pancreatic cysts (36 patients), concerning masses (30
269 patients), traumatic findings (44 patients), pancreatitis (41 patients), and ductal abnormalities
270 (19 patients).

271 By utilizing CT and MRI scans originally intended for the identification or evaluation of
272 conditions not related to pancreatic abnormalities, the algorithm we present in this study
273 offers a novel approach to the detection of PCLs. Our tool confirmed the incidental presence
274 of PCLs in 43.7% of the study population, in accordance with previously reported data [10].
275 Out of all confirmed cases, the SwinT-UNET-based algorithm correctly identified 91.6% of
276 them with a remarkable 91.6% sensitivity and 92.3% specificity, improving the results
277 reported by Duh et al., which were obtained with an algorithm specifically designed for the
278 classification of PCLs, not for their incidental detection. Furthermore, our algorithm is
279 capable of providing a comprehensive characterization of the PCL through its classification
280 as mucinous or non-mucinous with 73.3% accuracy. Although this result did not improve
281 those previously reported [24–27], the tool presented here can further characterize the PCL
282 by categorizing the lesion according to its location in the head, body, or tail of the pancreas
283 with 88.5% accuracy, as well as identifying the presence of calcifications or scars within the
284 PCL with 96% accuracy. Taken together, all this information provides a comprehensive
285 characterization of the lesion that, without any doubt, will be very valuable to clinicians for
286 the planning of tailored patient management strategies.

287 The results presented in this study were achieved using a robust dataset consisting of CT and
288 MRI studies obtained from eight different medical centers using scanners fabricated by four
289 different manufacturers. However, they are limited by the somewhat reduced number of
290 imaging studies included.

291

292 **CONCLUSIONS**

293 Our study presents comprehensive findings regarding the incidental detection and
294 characterization of PCLs through the integration of radiological data and advanced AI
295 techniques. The results reveal a substantial prevalence of PCLs within the studied population,
296 highlighting the importance of thorough radiological evaluations in clinical practice.

297 Our AI model, based on the SwinT-Unet architecture, showed a remarkable performance in
298 detecting PCLs with a sensitivity of 91.6% and a specificity of 92.3%. Furthermore, our study
299 contributes to the in-depth characterization of PCLs by distinguishing between mucinous and
300 non-mucinous types, aiding in risk stratification and clinical decision-making, and the
301 identification of calcifications or scars within the cystic lesions, an aspect crucial for the
302 assessment of potential signs of malignancy or chronic inflammation within the PCL. These
303 outcomes not only emphasize the clinical utility of our approach but also highlight the
304 potential of AI-driven approaches in enhancing the accuracy and efficiency of pancreatic
305 lesion detection, which will undoubtedly have a profound impact on patient management and
306 prognosis, particularly in the case of PCLs with malignant potential.

307

308

309 **DECLARATIONS**

310 **Funding**

311 This project was co-financed by the European Union (NextGenerationEU) through the Public
312 Business Entity Red.es, affiliated to the Secretaría de Estado de Digitalización e Inteligencia
313 Artificial, Ministerio de Asuntos Económicos y Transformación Digital (Secretary of State
314 for Digitalization and Artificial Intelligence, Ministry of Economic Affairs and Digital
315 Transformation) within the framework of the 2021 Call for Aid for research and development
316 projects in artificial intelligence and other digital technologies and their integration into value
317 chains (C005/21-ED call, project reference 2021/C005/00153960).

318

319 **Competing interests**

320 M. Álvaro Berbís is the CEO of Cells IA Technologies. Antonio Luna received institutional
321 royalties and institutional payments for lectures, presentations, speakers bureaus, manuscript
322 writing, or educational events from Canon, Bracco, Siemens Healthineers, and Philips
323 Healthcare and is a board member of Cells IA Technologies. Júlia Rodríguez-Comas is the
324 CTO of Sycal Technologies. The remaining authors have no competing interests to declare
325 that are relevant to the content of this article.

326

327 **Ethics approval**

328 This research was performed in accordance with the ethical standards in the 1964 Declaration
329 of Helsinki. The protocol followed in this study was approved by the Institutional Review
330 Board of HT Médica.

331

332 **Consent**

333 Written informed consent was obtained from the patients at the time of the performance of
334 the imaging study.

335

336 **Data, Materials, and/or Code availability**

337 The data used in this study are not openly available due to commercial and proprietary
338 constraints. Access to the data may be granted by the corresponding author upon reasonable
339 request and subject to confidentiality agreements.

340

341 **Authors' contributions**

342 Study conception and design were performed by M. Álvaro Berbís and Júlia Rodríguez-
343 Comas. Material preparation, data collection, and analysis were performed by M. Álvaro
344 Berbís, Juan Moreno-Vedia, Félix Paulano-Godino, Ainhoa Viteri, Meritxell Riera-Marín,
345 Daniel Cañadas-Gómez, Romina Trotta, Beatriz Forastero, Luis Luna, and Javier García
346 López. Supervision was performed by M. Álvaro Berbís and Júlia Rodríguez-Comas. The
347 first draft of the manuscript was written by M. Álvaro Berbís, Javier García López and Júlia
348 Rodríguez-Comas. Manuscript review and editing was performed by Antonio Luna. All

349 authors commented on previous versions of the manuscript. All authors read and approved
350 the final manuscript.

351

352 REFERENCES

- 353 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer
354 Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185
355 Countries. *CA Cancer J Clin.* 2021;71:209–49.
- 356 2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting Cancer
357 Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in
358 the United States. *Cancer Res.* 2014;74:2913–21.
- 359 3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin.* 2020;70:7–30.
- 360 4. Bengtsson A, Andersson R, Ansari D. The actual 5-year survivors of pancreatic ductal
361 adenocarcinoma based on real-world data. *Sci Rep.* 2020;10:16425.
- 362 5. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. *The Lancet.*
363 2011;378:607–20.
- 364 6. Kim J, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9
365 as a screening test for pancreatic cancer in an asymptomatic population. *J Gastroenterol Hepatol.*
366 2004;19:182–6.
- 367 7. Laffan TA, Horton KM, Klein AP, Berlanstein B, Siegelman SS, Kawamoto S, et al. Prevalence of
368 Unsuspected Pancreatic Cysts on MDCT. *American Journal of Roentgenology.* 2008;191:802–7.
- 369 8. Zhang X-M, Mitchell DG, Dohke M, Holland GA, Parker L. Pancreatic Cysts: Depiction on Single-
370 Shot Fast Spin-Echo MR Images. *Radiology.* 2002;223:547–53.
- 371 9. Lee KS, Sekhar A, Rofsky NM, Pedrosa I. Prevalence of Incidental Pancreatic Cysts in the Adult
372 Population on MR Imaging. *American Journal of Gastroenterology.* 2010;105:2079–84.
- 373 10. Kromrey M-L, Bülow R, Hübner J, Paperlein C, Lerch MM, Ittermann T, et al. Prospective study
374 on the incidence, prevalence and 5-year pancreatic-related mortality of pancreatic cysts in a
375 population-based study. *Gut.* 2018;67:138–45.
- 376 11. Jais B, Rebours V, Malleo G, Salvia R, Fontana M, Maggino L, et al. Serous cystic neoplasm of
377 the pancreas: a multinational study of 2622 patients under the auspices of the International
378 Association of Pancreatology and European Pancreatic Club (European Study Group on Cystic
379 Tumors of the Pancreas). *Gut.* 2016;65:305–12.
- 380 12. Tanaka M, Chari S, Adsay V, Carlos Castillo F-D, Falconi M, Shimizu M, et al. International
381 Consensus Guidelines for Management of Intraductal Papillary Mucinous Neoplasms and
382 Mucinous Cystic Neoplasms of the Pancreas. *Pancreatology.* 2006;6:17–32.
- 383 13. Maitra A, Adsay NV, Argani P, Iacobuzio-Donahue C, De Marzo A, Cameron JL, et al.
384 Multicomponent Analysis of the Pancreatic Adenocarcinoma Progression Model Using a Pancreatic
385 Intraepithelial Neoplasia Tissue Microarray. *Modern Pathology.* 2003;16:902–12.
- 386 14. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the
387 genetic evolution of pancreatic cancer. *Nature.* 2010;467:1114–7.


- 388 15. European evidence-based guidelines on pancreatic cystic neoplasms. *Gut*. 2018;67:789–804.
- 389 16. Tanaka M, Fernández-del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, et al. Revisions of
390 international consensus Fukuoka guidelines for the management of IPMN of the pancreas.
391 *Pancreatology*. 2017;17:738–53.
- 392 17. Atek S, Mehidi I, Jabri D, Belkhiat DEC. SwinT-Unet: Hybrid architecture for Medical Image
393 Segmentation Based on Swin transformer block and Dual-Scale Information. 2022 7th International
394 Conference on Image and Signal Processing and their Applications (ISPA). IEEE; 2022. p. 1–6.
- 395 18. Ronneberger O, Fischer P, Brox T. U-Net: Convolutional Networks for Biomedical Image
396 Segmentation. In: Navab N, Hornegger J, Wells WFA, editors. *Medical Image Computing and
397 Computer-Assisted Intervention – MICCAI 2015 MICCAI 2015 Lecture Notes in Computer Science()*.
398 2015. p. 234–41.
- 399 19. Huo Y, Tang Y, Chen Y, Gao D, Han S, Bao S, et al. Stochastic tissue window normalization of
400 deep learning on computed tomography. *Journal of Medical Imaging*. 2019;6:1.
- 401 20. Polk SL, Choi JW, McGettigan MJ, Rose T, Ahmed A, Kim J, et al. Multiphase computed
402 tomography radiomics of pancreatic intraductal papillary mucinous neoplasms to predict
403 malignancy. *World J Gastroenterol*. 2020;26:3458–71.
- 404 21. Anand N, Sampath K, Wu BU. Cyst features and risk of malignancy in intraductal papillary
405 mucinous neoplasms of the pancreas: A meta-analysis. *Clinical Gastroenterology and Hepatology*.
406 2013;11:913–21.
- 407 22. Udare A, Agarwal M, Alabousi M, McInnes M, Rubino JG, Marcaccio M, et al. Differentiation of
408 Benign and Malignant Pancreatic Cystic Lesions Compared to CT and Endoscopic Ultrasound:
409 Systematic Review and Meta-analysis. *J Magn Reson*. 2021;
- 410 23. Duh MM, Torra-Ferrer N, Riera-Marín M, Cumelles D, Rodríguez-Comas J, García López J, et al.
411 Deep Learning to Detect Pancreatic Cystic Lesions on Abdominal Computed Tomography Scans:
412 Development and Validation Study. *JMIR AI*. 2023;2:e40702.
- 413 24. Vilas-Boas F, Ribeiro T, Afonso J, Cardoso H, Lopes S, Moutinho-Ribeiro P, et al. Deep Learning
414 for Automatic Differentiation of Mucinous versus Non-Mucinous Pancreatic Cystic Lesions: A Pilot
415 Study. *Diagnostics*. 2022;12:2041.
- 416 25. Yang J, Guo X, Ou X, Zhang W, Ma X. Discrimination of Pancreatic Serous Cystadenomas From
417 Mucinous Cystadenomas With CT Textural Features: Based on Machine Learning. *Front Oncol*.
418 2019;9.
- 419 26. Shen X, Yang F, Yang P, Yang M, Xu L, Zhuo J, et al. A Contrast-Enhanced Computed Tomography
420 Based Radiomics Approach for Preoperative Differentiation of Pancreatic Cystic Neoplasm
421 Subtypes: A Feasibility Study. *Front Oncol*. 2020;10.
- 422 27. Gao X, Wang X. Performance of deep learning for differentiating pancreatic diseases on
423 contrast-enhanced magnetic resonance imaging: A preliminary study. *Diagn Interv Imaging*.
424 2020;101:91–100.

425 28. Kooragayala K, Crudeli C, Kalola A, Bhat V, Lou J, Sensenig R, et al. Utilization of Natural
426 Language Processing Software to Identify Worrisome Pancreatic Lesions. *Ann Surg Oncol*.
427 2022;29:8513–9.

428

429

430 **FIGURES**




431

432 **Fig1. Schematic representation of the Swin-Unet architecture.** The algorithm integrates
433 a Swin transformer-based encoder and a symmetrical Swin transformer-based decoder,
434 connected by two successive Swin transformer blocks (bottleneck).

435

436



437

438 **Fig2. Original images and predictions made by our algorithm. (A) Mucinous PCL. (B)**

439 **Non-mucinous PCL. Healthy pancreas is shown in purple, while the lesions appear in yellow.**

440

441

442 **TABLES**

443 **Table 1. Demographic and manufacturer distribution of the total cases included in the study.**

	Total Cases	<i>p</i>
Age (years)	66 (55-74)	
0-18	0	<0.001
19-40	3.7%	
41-60	32%	
61-80	60%	
81-100	4.3%	
Women	43.3%	0.021
Manufacturer		<0.001
Siemens	47%	
Philips	26.3%	
GE Medical systems	15.7%	
Canon Medical Systems	11%	

444

445

446 **Table 2. Demographic and manufacturer distribution of the control cases included in the study.**

	Control Cases	<i>p</i>
Age (years)	65 (56-72)	
0-18	0	<0,001
19-40	4.1 %	
41-60	32%	
61-80	61.2%	
81-100	1.8%	
Women	37.9%	0.002
Manufacturer		<0,001
Siemens	40.8%	
Philips	27.8%	
GE Medical systems	16%	
Canon Medical Systems	15.4%	

447

448

449

450

451

452

453

454 **Table 3. Demographic and manufacturer distribution of the PCL cases included in the study.**

	PCL Cases	<i>p</i>
Age (years)	68 (54-76)	
0-18	0	<0.001
19-40	3.1%	
41-60	32.1%	
61-80	57.3%	
81-100	7.6%	
Women	50.4%	0.930
Manufacturer		<0.001
Siemens	55%	
Philips	24.4%	
GE Medical systems	15.3%	
Canon Medical Systems	5.3%	

455 PCL: Pancreatic Cystic Lesion

456

457 **Table 4. Clinical and demographic characteristics of mucinous and non-mucinous PCLs.**

	Mucinous PCL	Non-mucinous PCL	<i>p</i>
SCN	-	70%	
Pseudocyst	-	23.8%	
Benign non-subclassifiable	-	3.8%	
Undetermined	-	2.5%	
IPMN	90.2%	-	
MCN	9.8%	-	
Age (years)	72 (64-79)	63 (51-74)	<0.001
0-18	0	0	
19-40	0	5%	
41-60	19.6%	40%	
61-80	68.6%	50%	
81-100	11.8%	5%	
Women	54.9%	47.5%	0.409

458 PCL: Pancreatic Cystic Lesion; SCN: Serous Cystic Neoplasms; IPMN: Intraductal Papillary Mucinous
 459 Neoplasms; MCN: Mucinous Cystic Neoplasms.

460

461

462